{
    "clinical_study": {
        "@rank": "131237", 
        "acronym": "Brightness", 
        "arm_group": [
            {
                "arm_group_label": "Arm A", 
                "arm_group_type": "Active Comparator", 
                "description": "Veliparib + carboplatin + paclitaxel followed by doxorubicin/cyclophosphamide (AC)"
            }, 
            {
                "arm_group_label": "Arm B", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo + carboplatin + paclitaxel followed by AC"
            }, 
            {
                "arm_group_label": "Arm C", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo + placebo + paclitaxel followed by AC."
            }
        ], 
        "brief_summary": {
            "textblock": "This is a 3 arm Phase 3 study to evaluate the safety and efficacy of the addition of\n      veliparib plus carboplatin versus the addition of carboplatin to standard neoadjuvant\n      chemotherapy versus standard neoadjuvant chemotherapy in subjects with early stage TNBC."
        }, 
        "brief_title": "A Study Evaluating Safety and Efficacy of the Addition of ABT-888 Plus Carboplatin Versus the Addition of Carboplatin to Standard Chemotherapy Versus Standard Chemotherapy in Subjects With Early Stage Triple Negative Breast Cancer", 
        "completion_date": {
            "#text": "June 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Triple Negative Breast Cancer", 
        "condition_browse": {
            "mesh_term": "Breast Neoplasms"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Histologically confirmed invasive breast cancer by core needle or incisional biopsy\n             (excisional biopsy is not allowed).  Clinical stage T2-4 N0-2 or T1 N1-2 by physical\n             exam or radiologic studies.\n\n          2. Documented Breast Cancer Gene (BRCA) germline mutation testing.\n\n          3. Estrogen Receptor (ER)-, Progesterone Receptor (PR)-, and Human Epidermal Growth\n             Factor Receptor (HER)2-negative (triple-negative) cancer of the breast.\n\n          4. ECOG Performance status of 0 to 1.\n\n          5. Women must be determined to be not of childbearing potential (surgically sterile, or\n             postmenopausal defined as amenorrheic for at least 12 months) by the Investigator OR\n             they must have a negative serum pregnancy test prior to randomization.\n\n        Exclusion Criteria:\n\n          1. Previous anti-cancer treatment (cytotoxic chemotherapy, immunotherapy, biologic\n             therapy radiotherapy or investigational agents) with therapeutic intent for current\n             breast cancer.\n\n          2. Previous treatment with carboplatin, paclitaxel, doxorubicin, cyclophosphamide and a\n             Poly-(ADP-ribose)-Polymerase (PARP) inhibitor.\n\n          3. Concurrent treatment with an ovarian hormonal replacement therapy or with hormonal\n             agents such as raloxifene, tamoxifen or other selective estrogen receptor modulator\n             (SERM).  Subjects must have discontinued use of such agents prior to beginning study\n             treatment.\n\n          4. A history of seizure within 12 months prior to study entry.\n\n          5. Pre-existing neuropathy from any cause in excess of Grade 1."
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "624", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 13, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02032277", 
            "org_study_id": "M14-011", 
            "secondary_id": "2013-002377-21"
        }, 
        "intervention": [
            {
                "arm_group_label": "Arm A", 
                "description": "Veliparib", 
                "intervention_name": "Veliparib", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Arm A", 
                    "Arm B"
                ], 
                "description": "Carboplatin", 
                "intervention_name": "Carboplatin", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Arm A", 
                    "Arm B", 
                    "Arm C"
                ], 
                "description": "Paclitaxel", 
                "intervention_name": "Paclitaxel", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Arm A", 
                    "Arm B", 
                    "Arm C"
                ], 
                "description": "Doxorubicin", 
                "intervention_name": "Doxorubicin", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Arm A", 
                    "Arm B", 
                    "Arm C"
                ], 
                "description": "Cyclophosphamide", 
                "intervention_name": "Cyclophosphamide", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Cyclophosphamide", 
                "Doxorubicin", 
                "Carboplatin", 
                "Paclitaxel"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "Oncology", 
            "Triple negative breast cancer", 
            "Austrian Breast & Colorectal Cancer Study Group - ABCSG 44", 
            "National Surgical Adjuvant Breast and Bowel Project - B-56-I", 
            "United States Oncology - 12152", 
            "Alliance - AFT-04", 
            "Grupo Espa\u00f1ol de Investigaci\u00f3n del C\u00e1ncer de Mama - GEICAM/2014-02", 
            "German Breast Group - GBG 81"
        ], 
        "lastchanged_date": "April 22, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Whittier", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "90603"
                    }, 
                    "name": "Site Reference ID/Investigator# 118035"
                }, 
                "investigator": {
                    "last_name": "Site Reference ID/Investigator# 118035", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Indianapolis", 
                        "country": "United States", 
                        "state": "Indiana", 
                        "zip": "46202"
                    }, 
                    "name": "Site Reference ID/Investigator# 118215"
                }, 
                "investigator": {
                    "last_name": "Site Reference ID/Investigator# 118215", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Lafayette", 
                        "country": "United States", 
                        "state": "Indiana", 
                        "zip": "47905"
                    }, 
                    "name": "Site Reference ID/Investigator# 116815"
                }, 
                "investigator": {
                    "last_name": "Site Reference ID/Investigator# 116815", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kansas City", 
                        "country": "United States", 
                        "state": "Missouri", 
                        "zip": "64111"
                    }, 
                    "name": "Site Reference ID/Investigator# 118775"
                }, 
                "investigator": {
                    "last_name": "Site Reference ID/Investigator# 118775", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Asheville", 
                        "country": "United States", 
                        "state": "North Carolina", 
                        "zip": "28806"
                    }, 
                    "name": "Site Reference ID/Investigator# 119179"
                }, 
                "investigator": {
                    "last_name": "Site Reference ID/Investigator# 119179", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Salt Lake City", 
                        "country": "United States", 
                        "state": "Utah", 
                        "zip": "84112"
                    }, 
                    "name": "Site Reference ID/Investigator# 118677"
                }, 
                "investigator": {
                    "last_name": "Site Reference ID/Investigator# 118677", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "3", 
        "official_title": "A Randomized, Placebo-Controlled, Double-Blind, Phase 3 Study Evaluating Safety and Efficacy of the Addition of Veliparib Plus Carboplatin Versus the Addition of Carboplatin to Standard Neoadjuvant Chemotherapy Versus Standard Neoadjuvant Chemotherapy in Subjects With Early Stage Triple Negative Breast Cancer (TNBC)", 
        "other_outcome": [
            {
                "description": "EFS will be defined as the time from random assignment to documentation of the first of the following events:  failure to reach potential curative surgery; local, regional, or distant invasive recurrence of breast cancer following curative surgery; a contralateral breast cancer; a new onset malignancy; or death as a result of any cause.", 
                "measure": "Event Free Survival (EFS)", 
                "safety_issue": "No", 
                "time_frame": "Up to 10 years from first dose of study drug."
            }, 
            {
                "description": "OS will be defined as the number of days from the day the subject is randomized to the date of the subject's death.", 
                "measure": "Overall Survival (OS)", 
                "safety_issue": "No", 
                "time_frame": "Up to 10 years from first dose of study drug."
            }, 
            {
                "description": "CRR at 12 weeks and tumor sizes at 12 weeks will be summarized at the end of the Chemotherapy Segment 1 of the treatment (reported at visit AC1) to assess the objective response rate. CRR is defined as the proportion of subjects with complete or partial response of the primary tumor as determined by the central imaging vendor.", 
                "measure": "Clinical Response Rate (CRR)", 
                "safety_issue": "No", 
                "time_frame": "First day of treatment on Chemotherapy Segment 2 (approximately 12-16 weeks from first dose of study drug)."
            }, 
            {
                "description": "RCB in the breast tissue and the lymph node tissue will be assessed upon completion of pre-operative systemic therapy and definitive surgery.", 
                "measure": "pCR plus minimal residual disease (defined as residual cancer burden [RCB] class I)", 
                "safety_issue": "No", 
                "time_frame": "At the time of definitive surgery (approximately 24-36 weeks from first dose of study drug)."
            }, 
            {
                "description": "ECOG performance status will be determined by the Investigator at each assessment.", 
                "measure": "Eastern Cooperative Oncology Group (ECOG) performance status.", 
                "safety_issue": "No", 
                "time_frame": "First day of treatment (Day 1) to Pre-Op Visit (approximately 22-32 weeks from first dose of study drug)."
            }, 
            {
                "description": "Breast cancer related QoL will be assessed via the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ-C30), Breast Cancer module (EORTC QLQ-BR23) and European Quality of Life 5 Dimensions 5 Level (EQ-5D-5L) questionnaires.", 
                "measure": "Breast cancer related quality of life (QoL).", 
                "safety_issue": "No", 
                "time_frame": "First day of treatment (Day 1) up to 6 months during the post-surgery follow-up period (approximately 15 months from first dose of study drug)."
            }
        ], 
        "overall_contact": {
            "email": "brian.oliver@abbvie.com", 
            "last_name": "Brian  Oliver, BS", 
            "phone": "847-938-5570"
        }, 
        "overall_contact_backup": {
            "email": "juliann.dziubinski@abbvie.com", 
            "last_name": "Juliannn  Dziubinski, BS", 
            "phone": "847-937-5838"
        }, 
        "overall_official": {
            "affiliation": "AbbVie", 
            "last_name": "Mark  McKee, MD", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "June 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Pathological complete response (pCR) in the breast tissue and the lymph node tissue will be assessed upon completion of pre-operative systemic therapy and definitive surgery.  Subjects who do not complete definitive surgery for reasons other than withdrawal of consent will be considered not to have achieved pCR.", 
            "measure": "Pathological Complete Response (pCR).", 
            "safety_issue": "No", 
            "time_frame": "At the time of definitive surgery (approximately 24-36 weeks from first dose of study drug)."
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02032277"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Whether a subject is eligible for breast conserving surgery will be determined by the subject's surgeon prior to chemotherapy and after completion of chemotherapy.", 
            "measure": "Rate of eligibility for breast conservation after therapy (BCR).", 
            "safety_issue": "No", 
            "time_frame": "At the time of definitive surgery (approximately 24-36 weeks from first dose of study drug)."
        }, 
        "source": "AbbVie", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "US Oncology Network", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "National Surgical Adjuvant Breast and Bowel Project (NSABP)", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Grupo Espanol de Investigacion del Cancer de Mama", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Austrian Breast & Colorectal Cancer Study Group", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Alliance for Clinical Trials in Oncology", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "German Breast Group", 
                    "agency_class": "Other"
                }
            ], 
            "lead_sponsor": {
                "agency": "AbbVie", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "January 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}